Inozyme stock draws Buy at Jefferies (NASDAQ:INZY)
Leo Patrizi Inozyme Pharma (NASDAQ:INZY) traded higher on Tuesday after Jefferies assumed coverage with a buy rating and a $17 price target, citing three rare disease opportunities for the company's flagship asset, INZ-701. Enzyme…
